Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India)

This article was originally published in PharmAsia News

Executive Summary

Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India) Major Indian pharmaceutical companies tend to accept out-of-court settlements of patent suits because they realize they need a continuous revenue flow from business abroad. Ranbaxy Laboratories, Dr. Reddy's, Lupin, Ranbaxy, Sun Pharma and Wockhardt have reached settlements by suing U.S. drug makers where in the past they might have pressed their claims in court. Each of the settled cases has involved a deal to be announced later guaranteeing a continued flow of income through the U.S. maker. Industry experts say those agreements are a sign generics makers are becoming more mature. (Click here for more )
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel